

癌症類別	大腸直腸癌
Neoadjuvant CCRT	<p>only for CCRT , for "local" rectal cancer :</p> <p>(1) 5-FU 425 mg/m² (N/S 500 c.c.; 4hrs)+ Leucovorin 100 mg (N/S 500 c.c.; 4hrs)/wk (JCO 1986; 4: 685-96)</p> <p>(2) UFUR 900-1100 mg/ m²/d +Leucovorin(P.O.) 30 mg/d</p>
Neoadjuvant	<p>Neoadjuvant C/T for colon cancer with invasion of adjacent structures :</p> <p>(1)(5-FU 1300 mg /m²/d + LV 200 mg/m²/d) N/S 500 c.c./d C.I. 2 days q 2wks (JCO 1997; 15: 808-15)</p> <p>(2) 5-FU 600 mg /m² (N/S 500 c.c. ; ≥3hrs) + LV 100 mg (N/S 500 c.c. ; ≥3hrs) q wk (JCO 1989; 7: 1407-17)</p> <p>(3) UFUR 900-1100 mg/m²/d +LV(P.O.) 30mg/d</p> <p>(4) (自費)Oxaliplatin 85 mg / m² (D5W 500 c.c.; ≥ 3 hrs)+5-FU / LV (劑量同上) q 2wks (或以 UFUR/LV (dose 同上) 或 Capecitabine 1250-1500 mg/ m²/d (2:1 or 5:2) 替代 V.5-FU) (Eur J.Cancer 1995; 31(S5))</p>
Adjuvant	<p>(I) Colorectal cancer , T ≥ subserosa or pericorectal tissues 且 LN(-) :</p> <p>(1) (5-FU 1300 mg /m²/d + LV 200 mg/m²/d) N/S 500 c.c./d C.I. 2 days q 2wks × 12 doses (JCO 1997; 15: 808-15)</p> <p>(2) 5-FU 600 mg /m² (N/S 500 c.c. ; ≥3hrs) + LV 100 mg (N/S 500 c.c. ; ≥3hrs) q wk × 24 doses (JCO 1989; 7: 1407-17)</p> <p>(3) UFUR 900-1100 mg/m²/d +LV(P.O.) 30mg/d × 6 months (使用期限可依健保給付規定 ; ≤ 2 years)</p> <p>(II) Colorectal cancer , stage III :</p> <p>(1) (5-FU 1300mg /m²/d + LV 200 mg/m²/d) N/S 500 c.c./d C.I. 2 days q 2wks × 24 doses</p> <p>(2) 5-FU 600 mg /m² + LV 100 mg (N/S 500 c.c. ; ≥3hrs) q wk × 48 doses</p> <p>(3) UFUR 900-1100 mg/m²/d +LV(P.O.) 30mg/d × 12 months (使用期限可依健保給付規定 ; for stage II, III only, ≤ 2 years)</p> <p>(4) Capecitabine 1250-1500 mg/ m²/d (2:1 or 5:2) × 6 months (Oncology Jan. 02, 2001) (使用期限可依健保給付規定 ; for stage III ; ≤ 8 months)</p> <p>(5) Oxaliplatin 85 mg / m² (D5W 500 c.c.; ≥ 3 hrs)+5-FU / LV (劑量同上) q 2wks x 12 doses (或以 UFUR/LV (dose 同上) 或 Capecitabine (dose 同上) 替代 V.5-FU) (Eur J.Cancer 1995; 31(S5))</p> <p>(III)M0,anyT or N with high risk(s) :</p> <p>(1) (5-FU 1300mg /m²/d + LV 200 mg/m²/d) N/S 500 c.c./d C.I. 2 days q 2wks × 24 doses</p> <p>(2) 5-FU 600 mg /m² + LV 100 mg (N/S 500 c.c. ; ≥3hrs) q wk × 48 doses</p> <p>(3) UFUR 900-1100 mg/m²/d +LV(P.O.) 30mg/d × 12 months (使用期限可依健保給付規定 ; ≤ 2 years)</p>

	<p>(4) Capecitabine 1250-1500 mg/ m²/d (2:1 or 5:2) × 6 months (Oncology Jan. 02, 2001) (使用期限可依健保給付規定；for stage III；≤ 8 months)</p> <p>(5) Oxaliplatin 85 mg/ m² (D5W 500 c.c.; ≥ 3 hrs)+5-FU / LV (劑量同上) q 2wks x 12 doses (或以 UFUR/LV (dose 同上) 或 Capecitabine (dose 同上)替代 V.5-FU) (Eur J.Cancer 1995; 31(S5))</p> <p>★High risk factors : poorly differentiated carcinoma、lymphatic/vascular invasion、perineural invasion、(near)bowel obstruction、bowel perforation、invasion of visceral peritoneum or adjacent tissue、≤11 lymph nodes sampled、margin positive or close (≤ 1mm)。</p>
<p>Palliative</p>	<p>Colorectal cancer , Stage IV :</p> <p>(1)(5-FU 1300 mg /m²/d+ LV 200 mg/m²/d) N/S 500 c.c./d C.I. 2 days q 2wks</p> <p>(2) 5-FU 600 mg /m² + LV 100 mg (N/S 500 c.c. ; ≥3hrs) q wk</p> <p>(3) UFUR 900-1100 mg/m²/d+LV(P.O.) 30mg/d</p> <p>(4) Capecitabine 1250-1500 mg/ m²/d (2:1 or 5:2)</p> <p>(5) Oxaliplatin 85 mg/ m² (D5W 500 c.c.; ≥ 3 hrs)+5-FU / LV(劑量同 Adjuvant) q 2wks (或以 UFUR/LV (dose 同上)或 Capecitabine (dose 同上)替代 V.5-FU) (Cancer Treat Rev. 2006 Nov; 32 (7): 491-503)</p> <p>(6) Irinotecan 140,150,160 mg/ m² (N/S 500 c.c. ; 3 hrs)+5-FU / LV (劑量同 Adjuvant) q 2wks (或以 UFUR/LV (dose 同上)或 Capecitabine (dose 同上)替代 V.5-FU)</p> <p>(7) Bevacizumab 5mg/kg/dose (N/S 100 c.c. ; 20 mins) (健保條例:可合併(1)~(6))</p> <p>(8) Aflibercept 3,4 mg/kg/dose (N/S 100 c.c. ; 1 hr)</p> <p>(9) Ramucirumab 8 mg/kg/dose (N/S 300 c.c. ; 90 mins)</p> <p>(10) Cetuximab 250 mg/m²/dose (2 hrs) (健保條例:可合併(6))</p> <p>(11) Panitumumab 6 mg/kg/dose (N/S 100 c.c.; 2 hrs) (健保條例:可合併(6))</p> <p>(12) Regorafenib 160 mg/d (3:1) (健保條例)</p> <p>(13) (自費)Tegafur & Gimeracil & Oteracil (TS-1) (2:1) : BSA < 1.25 m² : 40 mg bid ; BSA : 1.25-1.5 m² : 50 mg bid ; BSA ≥ 1.5 m² : 60 mg bid ; (ASCO Jun 6, 2013)</p> <p>(14) Lonsurf 35 mg/ m² bid (D1~5,D8~12) / q 28d</p>